A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
Alessandro Broccoli, Lisa Argnani, Matt Cross, Agnieszka Januś, Elsa Maître, Xavier Troussard, Tadeusz Robak, Claire Dearden, Monica Else, Daniel Catovsky, Pier Luigi Zinzani
Abstract
Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.
Topics & Concepts
CladribineHairy cell leukemiaMedicineLeukemiaMulticenter studyInternal medicineOncologyRandomized controlled trialChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentViral-associated cancers and disorders